8-K: Halozyme Sees Minimal Impact from New Medicare Price Guidance

Halozyme Therapeutics projects zero to minimal impact on its future royalty revenue from the U.S. Centers for Medicare & Medicaid Services' final IPAY 2028 guidance for Medicare Part B price negotiations.

Summary

• The U.S. Centers for Medicare & Medicaid Services (CMS) final guidance for Initial Price Applicability Year (IPAY) 2028 communicates no changes to the Part B policy for fixed combination products until 2029 at the earliest.
• Halozyme has demonstrated strong clinical and pharmacoeconomic evidence of the benefits of subcutaneous (SC) administration of ENHANZE partner products, including meaningful savings to Medicare and clinically meaningful patient benefits.
• Halozyme's interpretation of the IPAY Part B policy reinforces a zero to minimal impact on future partner royalties.
• The company projects zero royalty revenue impact in 2028, and zero to minimal impact for 2029-2031 and at least through 2035.
• U.S. Medicare Part B spend is projected to represent approximately 20% of total ENHANZE partner product global SC sales.

Sentiment

Score: 8

Explanation: The filing indicates a highly favorable outcome for Halozyme, as the anticipated negative impact from Medicare price negotiations for 2028 is projected to be zero, and minimal for subsequent years. Key products are excluded, and CMS policy changes are delayed. The company also highlights significant patient and cost benefits of its technology.

Positives

• CMS will maintain its existing fixed combination drug policy for IPAY 2028, delaying potential changes until 2029 at the earliest.
• Halozyme projects zero royalty revenue impact in 2028 from the IPAY 2028 guidance.
• Projected zero to minimal royalty revenue impact for 2029-2031 and at least through 2035.
• DARZALEX FASPRO is excluded from Part B negotiations in 2028 due to all indications having orphan designation.
• Opdivo is excluded from Part B negotiations in 2028 as its first indication has orphan designation, delaying potential impact to 2029 unless a biosimilar launches.
• SC delivery of 5 of 7 biologic drugs resulted in meaningful cost savings to Medicare compared with IV delivery, with DARZALEX FASPRO showing ~$29,000 annualized savings per patient per year.
• 89.6% of patients indicated a preference towards SC delivery versus 5.5% towards IV, often owing to a reduced treatment burden and improved independence, convenience, and ability to cope with their illness.
• SC delivery with ENHANZE offers benefits like meaningfully lower incidence of infusion-related reactions, improved overall survival, reduced treatment time, and lower infection risk.

Negatives

• CMS intends to address the program integrity risk related to manufacturers using the fixed combination drug policy to avoid aggregation and negotiation, potentially leading to policy changes in rulemaking beginning in IPAY 2029.

Risks

• Unexpected levels of revenues received from Medicare Part B sales.
• Unexpected changes in the exclusions to Medicare price negotiations.
• Delays in the launch of biosimilars referred to in this presentation.
• Unexpected adverse events or patient outcomes.
• Competitive conditions and uncertainties related to future pharmaceutical pricing policies.

Future Outlook

Halozyme expects zero to minimal impact on its future royalty revenue from the IPAY 2028 Medicare Part B price negotiations, with no changes to the fixed combination drug policy until 2029 at the earliest. The company projects continued exclusion for key products like DARZALEX FASPRO and Opdivo in 2028 due to orphan drug designations, and potential delays for others like Vyvgart and Rybrevant until 2035 or later. Halozyme is committed to ongoing clinical and pharmacoeconomic research to demonstrate the value of ENHANZE SC administered products.

Management Comments

• Halozyme is committed to continue clinical and pharmacoeconomic research to demonstrate the value of ENHANZE SC administered products.

Industry Context

The U.S. Centers for Medicare & Medicaid Services' (CMS) final IPAY 2028 guidance for Medicare price negotiations, particularly regarding Part B drugs, is a critical development for pharmaceutical companies. Halozyme's statement highlights the industry's focus on understanding and mitigating the impact of the Inflation Reduction Act (IRA) on drug pricing and revenue. The decision to maintain the existing fixed combination drug policy for 2028 provides a temporary reprieve for companies like Halozyme, but CMS's intent to address 'program integrity risk' in 2029 indicates ongoing regulatory scrutiny and potential future policy changes. The emphasis on orphan drug exclusions and the impact of biosimilar launches are key factors shaping market dynamics and strategic planning for drug developers.

Comparison to Industry Standards

• The filing references a peer-reviewed study in the Journal of Medical Economics (2025) comparing SC versus IV delivery of select therapies, demonstrating meaningful cost savings to Medicare for 5 of 7 biologic drugs.
• The study specifically highlighted annualized savings for DARZALEX FASPRO of approximately $29,000 per patient per year when delivered subcutaneously.
• Another peer-reviewed study in Oncology and Therapy Journal (2025) presented real-world patient preferences, showing 89.6% of cancer patients preferred SC delivery over 5.5% for IV, indicating a strong patient-centric benefit for Halozyme's technology compared to traditional IV administration.

Stakeholder Impact

• Shareholders: Positive impact due to projected minimal to zero impact on royalty revenue from Medicare price negotiations, reducing a significant regulatory risk.
• Patients: Positive impact through continued access to ENHANZE-enabled subcutaneous therapies, which offer clinically meaningful benefits, reduced treatment burden, and improved comfort compared to intravenous administration.
• Healthcare System/Medicare: Positive impact through demonstrated cost savings associated with subcutaneous delivery of certain biologic drugs, potentially lowering overall healthcare expenditures.

Next Steps

• CMS intends to address the program integrity risk related to fixed combination drugs in rulemaking beginning in initial price applicability year 2029.
• Halozyme is committed to continue clinical and pharmacoeconomic research to demonstrate the value of ENHANZE SC administered products.

Key Dates

Recommendation

The filing significantly de-risks a major overhang for Halozyme related to Medicare Part B price negotiations. The projected zero impact on royalty revenue for 2028 and minimal impact through 2035, coupled with the delay in CMS policy changes for fixed combination drugs, removes a key uncertainty. The continued exclusion of major partner products like DARZALEX FASPRO and Opdivo from 2028 negotiations is highly favorable. Furthermore, the demonstrated clinical and pharmacoeconomic benefits of ENHANZE technology, including significant cost savings to Medicare and strong patient preference for SC delivery, reinforce the long-term value proposition of Halozyme's platform. This positive regulatory clarity and strong underlying product value make the stock a strong buy.

Keywords

Halozyme Therapeutics, HALO, Medicare, CMS, IPAY 2028, Drug Price Negotiation, ENHANZE, Royalty Revenue, Subcutaneous Delivery, Orphan Drug, Biosimilars, Pharmaceutical Pricing, Healthcare Costs, DARZALEX FASPRO, Opdivo, Vyvgart, Rybrevant